Inge Marie Svane

Inge Marie Svane

Clinical Professor

Member of:

  • Clinical Oncology


  1. Published

    The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy

    Ahmad, S. M., Martinenaite, E., Holmström, M., Jørgensen, M. A., Met, Özcan, Nastasi, C., Klausen, U., dqp123, dqp123, Pedersen, Lars Møller, Munksgaard, Lars, Ødum, Niels, Woetmann, Anders , Svane, Inge Marie & Andersen, Mads Hald, 2018, In: OncoImmunology. 7, 2, 10 p., e1390641.

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Published

    Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway

    Ahmad, S. M., Larsen, S. K., Svane, Inge Marie & Andersen, M. H., Jan 2014, In: Leukemia. 28, 1, p. 236-238 3 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    Cancer treatment: the combination of vaccination with other therapies

    Andersen, M. H., Sorensen, R. B., Schrama, D., Becker, J. C., Straten, P. T. & Svane, Inge Marie, 2008, In: Cancer Immunology, Immunotherapy. 57, 11, p. 1735-1743 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    Immunogenicity of Bcl-2 in patients with cancer

    Andersen, M. H., Svane, Inge Marie, Kvistborg, P., Nielsen, O. J., Balslev, E., Reker, S., Becker, J. C. & Straten, P. T., 15 Jan 2005, In: Blood. 105, 2, p. 728-34 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Published

    Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients

    Andersen, Mads Hald, Sørensen, R. B., Brimnes, M. K., Svane, Inge Marie, Becker, J. C. & thor Straten, P., 2009, In: Journal of Clinical Investigation. 119, 8, p. 2245-56 12 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    Therapeutic cancer vaccines in combination with conventional therapy

    Andersen, Mads Hald, Junker, N., Ellebaek, E., Svane, Inge Marie, Thor Straten, P. & Andersen, Mads Hald, 1 Jan 2010, In: Journal of Biomedicine and Biotechnology. 2010, p. 237623

    Research output: Contribution to journalJournal articleResearchpeer-review

  7. Published

    Indoleamine 2,3-dioxygenase vaccination

    Andersen, Mads Hald & Svane, Inge Marie, 2015, In: OncoImmunology. 4, 1, p. 1-3 3 p., e983770.

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. Published

    T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression

    Andersen, R., Borch, T. H., Draghi, A., Gokuldass, A., Rana, M. A. H., Pedersen, M., Nielsen, M., Kongsted, P., Kjeldsen, J. W., Westergaard, M. C. W., Radic, H. D., Chamberlain, C. A., Hølmich, Lisbet Rosenkrantz, Hendel, Helle Westergren, Larsen, M. S., Met, Özcan, Svane, Inge Marie & dqp123, dqp123, 2018, In: Annals of Oncology. 29, 7, p. 1575-1581 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  9. Published

    Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma

    Andersen, R., Donia, M., Westergaard, M. C. W., Pedersen, M., Hansen, M. & Svane, Inge Marie, 2015, In: Human Vaccines & Immunotherapeutics. 11, 12, p. 2790-5 6 p.

    Research output: Contribution to journalComment/debateResearch

  10. Published

    Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab

    Andersen, R., Nørgaard, P. H., Al-Jailawi, M. K. M. & Svane, Inge Marie, 23 Jan 2014, In: OncoImmunology. 3, 8, e954506.

    Research output: Contribution to journalJournal articleResearchpeer-review

Previous 1 2 3 4 5 6 7 8 ...28 Next

ID: 4054758